Natural compound inducers of immunogenic cell death by Diederich, Marc
Trends in Natural Product Research – PSE Young Scientists’ Meeting 








Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National 




Accumulating evidence documents the anticancer potential of the immune response 
that can be re-established by modulating the immunogenicity of dying cancer cells. This 
regulated cell death process is called immunogenic cell death (ICD) and constitutes a 
new innovating anti-cancer strategy with immune-modulatory potential thanks to the 
release of damage-associated molecular patterns (DAMPs). Some conventional 
clinically-used chemotherapeutic drugs as well as preclinically-investigated compounds 
of natural origins such as anthracyclines, microtubule-destabilizing agents, cardiac 
glycosides or hypericin derivatives possess such an immune-stimulatory function by 
triggering ICD. In this review, we summarize the effects of ICD inducers on DAMP 
signaling leading to immune recognition. We will discuss potential strategies allowing 
to overcome resistance mechanisms associated with this treatment approach as well as 
co-treatment strategies to overcome the immunosuppressive microenvironment. We 
will highlight the potential role of metronomic immune modulation as well as targeted 
delivery of ICD-inducing compounds with nanoparticles or liposomal formulations to 
improving immunogenicity of ICD inducers aiming at long-term clinical benefits. 
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